Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer

Amanda Myers; Benjamin Ristau; Matthew Mossanen; Mark D. Tyson; Stephanie Chisolm; Frank Sloan; Colleen T. Ball; Angela Smith; Timothy D. Lyon

doi:10.1016/j.urolonc.2023.09.006

Back

Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer

Journal article

Open access

Peer reviewed

Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer

Amanda Myers, Benjamin Ristau, Matthew Mossanen, Mark D. Tyson, Stephanie Chisolm, Frank Sloan, Colleen T. Ball, Angela Smith and Timothy D. Lyon

Urologic oncology, Vol.42(2), pp.29.e17-29.e22

02/2024

DOI: 10.1016/j.urolonc.2023.09.006

PMID: 37993341

Files and links (1)

url

https://doi.org/10.1016/j.urolonc.2023.09.006View

Published (Version of record) Open Access

Abstract

To quantify patient reported treatment burden while receiving intravesical therapy for bladder cancer and to survey patient perspectives on in-home intravesical therapy. We conducted a cross-sectional survey of the Bladder Cancer Advocacy Network Patient Survey Network. Survey questions were developed by investigators, then iteratively revised by clinician and patient advocates. Eligible participants had to have received at least 1 dose of intravesical therapy delivered in an ambulatory setting. Two hundred thirty-three patients responded to the survey with median age of 70 years (range 33–88 years). Two-thirds of respondents (66%, 151/232) had received greater than 12 bladder instillations. A travel time of >30 minutes to an intravesical treatment facility was reported by 55% (126/231) of respondents. Fifty-six percent (128/232) brought caregivers to their appointments, and 36% (82/230) missed work to receive treatment. Sixty-one respondents (26%) felt the process of receiving bladder instillations adversely affected their ability to perform regular daily activities. Among those surveyed, 72% (168/232) reported openness to receiving in-home intravesical instillations and 54% (122/228) answered that in-home instillations would make the treatment process less disruptive to their lives. Bladder cancer patients reported considerable travel distances, time requirements, and need for caregiver support when receiving intravesical therapy. Nearly three-quarters of survey respondents reported openness to receiving intravesical instillations in their home, with many identifying potential benefits for home over clinic-based therapy.

Bacillus Calmette-Guerin

Bladder cancer

Intravesical instillation

Patient outcome assessment

Surveys and Questionnaires

Details

Title: Subtitle: Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer
Creators: Amanda Myers - The University of Texas MD Anderson Cancer Center
Benjamin Ristau - UConn Health
Matthew Mossanen - Brigham and Women's Hospital
Mark D. Tyson - Mayo Clinic in Arizona
Stephanie Chisolm - Bladder Cancer Advocacy Network
Frank Sloan - Duke University
Colleen T. Ball - Mayo Clinic in Florida
Angela Smith - University of North Carolina at Chapel Hill
Timothy D. Lyon - Mayo Clinic in Florida
Resource Type: Journal article
Publication Details: Urologic oncology, Vol.42(2), pp.29.e17-29.e22
DOI: 10.1016/j.urolonc.2023.09.006
PMID: 37993341
NLM abbreviation: Urol Oncol
ISSN: 1078-1439
eISSN: 1873-2496
Publisher: Elsevier Inc
Language: English
Date published: 02/2024
Academic Unit: Urology
Record Identifier: 9984934669102771

Metrics

5 Record Views

See more details